8-K: Tharimmune Secures $1.74 Million Through Registered Direct Offering and Private Placement

Tharimmune, Inc. announced the pricing of a $1.74 million registered direct public offering of common stock and pre-funded warrants, alongside a concurrent private placement of common warrants, to fund working capital and general corporate purposes.

Summary

• Tharimmune, Inc. priced a registered direct public offering and a concurrent private placement, raising approximately $1.74 million in gross proceeds.
• The offering includes 414,331 shares of Common Stock and 559,910 pre-funded warrants to acquire Common Stock.
• A concurrent private placement includes 974,241 common warrants to acquire shares of Common Stock.
• The price per unit, consisting of one share of Common Stock (or pre-funded warrant) and one common warrant, is $1.786.
• The pre-funded warrants have a nominal exercise price of $0.001 per share.
• The common warrants have an exercise price of $1.66 per share.
• President Street Global, LLC acted as the exclusive lead placement agent for the offering.
• The company will pay President Street Global a cash fee of 7.0% of the aggregate gross proceeds from the sale of units and 7.0% of the aggregate proceeds from the exercise of the common warrants.
• The offering closed on July 25, 2025.

Sentiment

Score: 5

Explanation: The filing indicates a successful capital raise, which is positive for a clinical-stage biotech company needing funds for operations. However, the significant placement agent fees and the disclosed potential conflict of interest introduce elements of concern, balancing the overall sentiment to neutral.

Positives

• Successfully raised approximately $1.74 million in gross proceeds, providing capital for working capital and general corporate purposes.
• The offering includes pre-funded warrants with a nominal exercise price of $0.001, which can attract investors seeking immediate equity exposure with minimal upfront cash outlay for exercise.

Negatives

• The offering involves the issuance of new shares and warrants, which will result in dilution for existing shareholders.
• Significant fees are payable to the placement agent, totaling 7.0% of gross proceeds and an additional 7.0% on common warrant exercises, reducing net proceeds.
• A potential conflict of interest exists as an investment manager at the company's largest shareholder (Gravitas Capital LP) is also an indirect owner of the placement agent (President Street Global, LLC), potentially benefiting from the fees.

Risks

• The securities offered have not been registered with the SEC or state securities commissions, relying on exemptions from registration, which restricts their immediate resale.
• The company is required to file a resale registration statement for the common warrants and underlying shares, and failure to do so or maintain its effectiveness could impact the liquidity for investors.
• The market price of the company's publicly-traded securities may be negatively impacted by past or future open market or other transactions by purchasers, including short sales or derivative transactions.
• Hedging activities by purchasers could reduce the value of existing stockholders' equity interests.
• The company's ability to maintain its listing on Nasdaq Capital Market is crucial, and failure to comply with listing requirements could negatively impact liquidity and investor confidence.

Future Outlook

The company intends to use the net proceeds from the offering for working capital and general corporate purposes. It has agreed to file a resale registration statement covering the common warrants and underlying shares to enable their future trading upon registration or qualification under applicable laws.

Industry Context

This capital raise provides Tharimmune, a clinical-stage biotechnology company, with additional funding to support its diverse portfolio of therapeutic candidates in immunology, inflammation, and oncology. Such offerings are common for biotech companies to finance ongoing research and development, clinical trials, and general operations, especially given the long development cycles and high capital requirements in the sector.

Comparison to Industry Standards

• The 7.0% placement agent fee on gross proceeds is within the typical range for registered direct offerings in the biotechnology sector, which can vary based on deal size and market conditions.
• The inclusion of warrants in the offering is a common practice in small-cap biotech capital raises, often used to sweeten the deal for investors and provide additional upside potential, though it also contributes to future dilution.

Related Party Transactions

• Vincent LoPriore, an investment manager at Gravitas Capital LP (the largest shareholder of Tharimmune), is also an indirect owner of the holding company of President Street Global, LLC, the exclusive lead placement agent for this offering. Mr. LoPriore may indirectly benefit from the cash fees paid to President Street Global, LLC.

Stakeholder Impact

• Shareholders: Will experience dilution due to the issuance of new shares and warrants. The potential conflict of interest with the placement agent may raise governance concerns.
• Investors (Purchasers): Will acquire common stock, pre-funded warrants, and common warrants, providing them with equity exposure and potential upside, subject to exercise and market conditions. They are responsible for their own SEC filings related to beneficial ownership.
• Company Operations: The capital raise provides necessary funding for working capital and general corporate purposes, supporting ongoing research and development and strategic initiatives.

Next Steps

• The company will file a Current Report on Form 8-K, including the Transaction Documents as exhibits.
• The company has agreed to file a resale registration statement covering the common warrants and underlying shares to enable their future trading upon registration or qualification under applicable laws.
• The company will apply to list or quote all of the Shares and Warrant Shares on its principal Trading Market and promptly secure their listing.

Key Dates

Recommendation

The capital raise provides essential funding for Tharimmune's operations and pipeline, which is a positive for a clinical-stage biotech. However, the significant dilution from the offering, coupled with substantial placement agent fees and a disclosed conflict of interest, introduces notable concerns. While the funding is critical, these factors suggest a 'hold' recommendation, as the immediate benefits of the capital infusion are offset by the costs and potential governance issues, warranting a cautious approach until further operational progress or clearer financial impacts are observed.

Keywords

Tharimmune, Registered Direct Offering, Private Placement, Common Stock, Pre-Funded Warrants, Common Warrants, Capital Raise, Biotechnology, Immunology, Inflammation, Oncology, SEC Filing, THAR, Nasdaq Capital Market